La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Addentax Group a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Addentax Group..

Addentax Group (NASDAQ:ATXG) Azioni, Catena delle Opzioni

Addentax Group

Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.

Addentax Group Corp

WIIM

UXIN

Uxin shares are trading higher after the company reported Q2 sales of $70.85 million, up from $48.80 million year-over-year.

Macy's shares are trading lower after the company delayed its Q3 earnings release and conference call, citing an issue related to delivery expenses in one of its accrual accounts, prompting an independent investigation.

BBWI

Bath & Body Works shares are trading higher after the company reported better-than-expected Q3 EPS and sales and raised its 2024 guidance.

Rosenblatt analyst Catharine Trebnick maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and raises the price target from $325 to $385.

News

Price Target

Analyst Ratings

CRWD

Rosenblatt Maintains Buy on CrowdStrike Holdings, Raises Price Target to $385

The study is evaluating the safety, tolerability, efficacy, pharmacokinetics, and biomarkers of orally administered PL8177 in adult patients with active ulcerative colitis.

Biotech

Health Care

General

Palatin Technologies Has Completed Enrollment In Its Phase 2 Study Of PL8177 For Ulcerative Colitis, The Last Patient Visit Is Expected To Occur In Q1 Of 2025, With Topline Data Expected Shortly Thereafter

HC Wainwright &amp; Co. analyst Mitchell Kapoor initiates coverage on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell rating and announces Price Target of $80.

Initiation

SRPT

HC Wainwright & Co. Initiates Coverage On Sarepta Therapeutics with Sell Rating, Announces Price Target of $80

Cognition Therapeutics, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>), a clinical-stage company developing drugs to treat neurodegenerative disorders, provided an update on a biomarker(1) analysis from the Phase 2 'SHINE' study in mild-to-moderate Alzheimer's disease. This new analysis focused on plasma samples from all participants who entered the study with lower levels of plasma p-tau217(2) . Several blood-based measures of Alzheimer's disease biology were identified that were normalized in CT1812-treated participants compared to the placebo-treated participants. These biomarker changes occurred in concert with a 95% slowing of cognitive decline as measured by ADAS-Cog11 in the same patients. These data provide further evidence that CT1812 may be preserving cognitive function and slowing disease progression by protecting key neurological system. &nbsp;

CGTX

Cognition Therapeutics Announced 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer's Disease Biology

Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.05 by 300 percent. The company reported quarterly sales of $7.194 million which beat the analyst consensus estimate of $7.000 million by 2.77 percent. This is a 6.58 percent increase over sales of $6.750 million the same period last year.

Earnings

Earnings Beats

ALAR

Alarum Technologies Q3 2024 Adj. EPS $0.20 Beats $0.05 Estimate, Sales $7.194M Beat $7.000M Estimate

BHVN

Biohaven Says In RESILIENT SMA Study, Taldefgrobep Alfa Showed Clinically Meaningful Improvements In Motor Function At All Timepoints On The Motor Function Measurement-32 Scale, But The Treatment Arm Did Not Statistically Separate On The Primary Outcome At Week 48 Compared To The Placebo+Standard Of Care Group

Contracts

SRM Entertainment Announces Order From An Orlando Theme Park For Its Misting Fans; Initial Order Of $820K For US Theme Parks And $85K For International Parks

AVXL

Anavex Life Sciences Announces Acceptance Of Peer-Reviewed Manuscript Titled 'Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial' In A Reference Alzheimer's Disease Journal

Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares are trading higher premarket on Monday after the company successfully completed its 56th Electron mission and finalized a&nbsp;$23.9 million&nbsp;award from the U.S. Department of Commerce.
The company deployed five satellites into Low Earth Orbit for French IoT constellation operator Kinéis.
Rocket Lab&#8217;s &#8220;Ice AIS Baby&#8221; mission successfully launched from New Zealand on November 25, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42156903/rocket-lab-successfully-launches-two-missions-in-less-than-24-hours" rel="noreferrer noopener">deploying five satellites into a 643 km orbit.</a>
The company set a record for its fastest turnaround, completing the launch just 21 hours and 55 minutes after another mission in Virginia.
This marks Rocket Lab&#8217;s 14th mission of 2024 and its 56th overall, bringing its total satellites launched to 203.
Rocket Lab founder and CEO Sir Peter Beck said, &#8220;Two successful launches less than 24 hours apart from pads in different hemispheres. That&#8217;s unprecedented capability in the small launch market and one we&#8217;re immensely proud to deliver at Rocket Lab.&#8221;
Kinéis CEO Alexandre Tisserant, added, &#8221;With 15 Kinéis satellites now in orbit, we&#8217;re one step closer to the full deployment of our dedicated IoT constellation for transmitting data in near-real time, anywhere on the globe.&#8221;
Apart from this, in a seperate release, Rocket Lab disclosed that it finalized&nbsp;a $23.9 million award from the U.S. Department of Commerce to expand its compound semiconductor<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42160043/rocket-lab-signs-23-9m-chips-incentives-award-to-boost-semiconductor-manufacturing" rel="noreferrer noopener"> manufacturing in Albuquerque, New Mexico</a>.
These semiconductors are critical for space-grade solar cells and optoelectronic products essential to national security and commercial applications.
This month, the company also announced a multi-launch agreement with a confidential customer and was awarded a&nbsp;defense contract <a target="_blank" href="https://www.benzinga.com/news/contracts/24/11/41941068/rocket-lab-stock-is-blasting-off-wednesday-whats-going-on" rel="noreferrer noopener">worth up to $8 million</a>.
Investors can gain exposure to the stock via&nbsp;Procure Space ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFO#NASDAQ">UFO</a>) and&nbsp;SPDR S&amp;P Kensho Final Frontiers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROKT#NYSE">ROKT</a>).
Price Action: RKLB shares are up 7.7% at $25.05 premarket at the last check Monday.
Photo via Company
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin" target="_blank" rel="noreferrer noopener">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Equities

Mid Cap

Movers

RKLB

ROKT

Why Is Rocket Lab USA Stock Surging Today?

Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) for the treatment of hereditary transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN). Nex-z is an in vivo&nbsp;CRISPR-based investigational&nbsp;therapy designed as a single-dose treatment to inactivate the&nbsp;TTR&nbsp;gene and thereby prevent the production of TTR protein for the treatment of ATTR amyloidosis. Development and commercialization of nex-z is led by Intellia as part of a multi-target collaboration with Regeneron.
"This RMAT designation underscores the transformative potential of nex-z, our investigational in vivo CRISPR-based gene editing therapy for those living with hereditary ATTR amyloidosis with polyneuropathy," said Intellia President and Chief Executive Officer John Leonard, M.D. "It was granted following the FDA's review of our compelling interim Phase 1 data that indicated our one-time treatment led to rapid, deep and durable TTR reduction, which is expected to halt and potentially reverse the disease. We look forward to working closely with the FDA to bring this potential paradigm-shifting therapy to patients as quickly as possible."
The RMAT designation was established under the 21st Century Cures Act to expedite the development and review of promising therapeutic candidates, including genetic therapies, that are intended to treat, modify, reverse or cure a serious or life-threatening disease. RMAT designation includes benefits, such as early interactions with the FDA, including discussions on surrogate or intermediate endpoints that could potentially support accelerated approval and satisfy post-approval requirements, and potential priority review of a product's biologics license application (BLA).
This RMAT designation is the third special regulatory designation received by Intellia for nex-z. Nex-z was also granted Orphan Drug Designation by the U.S. FDA and European Union Orphan Drug Designation by the European Commission.
About nexiguran ziclumeran (nex-z, also known as NTLA-2001) Based on Nobel Prize-winning CRISPR/Cas9 technology, nex-z has the potential to become the first one-time treatment for transthyretin (ATTR) amyloidosis. Nex-z is designed to inactivate the&nbsp;TTR&nbsp;gene that encodes for the transthyretin (TTR) protein. Interim Phase 1 clinical data showed the administration of nex-z led to consistent, deep and long-lasting TTR reduction. Intellia leads development and commercialization of nex-z as part of a multi-target discovery, development and commercialization&nbsp;collaboration&nbsp;with Regeneron.

Government

Regulations

NTLA

Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost

Morgan Stanley analyst Toni Kaplan upgrades KinderCare Learning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) from Equal-Weight to Overweight and announces $30 price target.

Upgrades

Morgan Stanley Upgrades KinderCare Learning to Overweight, Announces $30 Price Target

Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>, "Cassava", the "Company"))), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for Alzheimer's disease (AD) dementia, today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints. The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 52, assessed by the ADAS-COG12 and ADCS-ADL scales, comparing simufilam to placebo. Simufilam continued to demonstrate an overall favorable safety profile. The Company will hold a webcast today at 8 AM ET.
"The results are disappointing for patients and their families who are living with this disease and physicians who have been looking for novel treatment options. We took careful measures to enroll patients with mild-to-moderate AD. Despite that, the loss of cognition in the placebo group was less pronounced than was previously reported in other placebo-controlled studies in AD. We are working to understand this better," said Rick Barry, President and Chief Executive Officer. "A result like this has implications on our second Phase 3 trial,&nbsp;ReFocus-ALZ. We have made the difficult decision to discontinue ReFocus-ALZ, given the nature of today's reported results. The complete 52-week dataset will be available from the study along with a large portion of 76-week data. We intend to report detailed analyses of both studies in the future. We will also be discontinuing the Open Label Extension study."
Mr. Barry continued, "We have a special gratitude for the patients and their families and caregivers who participated in our clinical program for AD. We are also immensely grateful to our employees, study investigators and site coordinators, as well as our other partners, for their commitment to this program. We hope the information we have gathered can ultimately be used to benefit ongoing research in AD."
The table below provides a high-level summary of the co-primary endpoints data. Topline analysis of the mild and moderate sub-groups, likewise, did not demonstrate statistical significance at week 52.
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Co-Primary Endpoint Data&#x2A;</td>
<td>Simufilam 100 mg BID N= 403</td>
<td>Placebo BID N=401</td>
<td>Delta</td>
<td>P-value</td>
</tr>
<tr>
<td colspan="5">Co-Primary Endpoints LS means change from baseline to the end of the double-blind treatment period</td>
</tr>
<tr>
<td>ADAS-COG12 (SE)</td>
<td>2.8 ( 0.36)</td>
<td>3.2 ( 0.36)</td>
<td>-0.39 ( 0.50)</td>
<td>P=0.43</td>
</tr>
<tr>
<td>ADCS-ADL (SE)</td>
<td>-3.3 ( 0.44)</td>
<td>-3.8 ( 0.44)</td>
<td>0.51 ( 0.61)</td>
<td>P=0.40</td>
</tr>
<tr>
<td colspan="5">&#x2A;Based on the intent-to-treat population BID = twice daily ADAS-COG12 = The Alzheimer's Disease Assessment Scale – Cognitive Subscale (a lower number represents less cognitive impairment) ADCS-ADL = Alzheimer's Disease Cooperative Study – Activities of Daily Living (a higher number represents less functional impairment)</td>
</tr>
</tbody>
</table>
</figure>
The table below provides a high-level summary of the patient demographic and safety data. Simufilam continued to demonstrate an overall favorable safety profile.
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Metrics for Simufilam and Placebo</td>
<td>Simufilam 100 mg BID</td>
<td>Placebo BID</td>
</tr>
<tr>
<td colspan="3">Baseline&#x2A;</td>
</tr>
<tr>
<td>Age, mean (SD), in years</td>
<td>73.7 7.9</td>
<td>74.3 7.6</td>
</tr>
<tr>
<td>Sex, n (%) female</td>
<td>225 (55.8%)</td>
<td>222 (55.4%)</td>
</tr>
<tr>
<td>MMSE Score (No.%,)</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>21-27</td>
<td>244 (60.5%)</td>
<td>250 (62.3%)</td>
</tr>
<tr>
<td>16-20</td>
<td>155 (38.5%)</td>
<td>146 (36.4%)</td>
</tr>
<tr>
<td>Race/Ethnicity</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>White</td>
<td>366 (90.8%)</td>
<td>376 (93.8%)</td>
</tr>
<tr>
<td>Black</td>
<td>20 (5.0%)</td>
<td>18 (4.5%)</td>
</tr>
<tr>
<td>Asian</td>
<td>8 (2.0%)</td>
<td>2 (0.5%)</td>
</tr>
<tr>
<td>Other</td>
<td>9 (2.2%)</td>
<td>5 (1.0%)</td>
</tr>
<tr>
<td colspan="3">Safety&#x2A;&#x2A;</td>
</tr>
<tr>
<td>Any Adverse Event (AE)</td>
<td>284 (71.2%)</td>
<td>269 (67.6%)</td>
</tr>
<tr>
<td>Serious AEs</td>
<td>52 (13.0%)</td>
<td>36 (9.0%)</td>
</tr>
<tr>
<td>Death</td>
<td>1 (0.3%)</td>
<td>3 (0.8%)</td>
</tr>
<tr>
<td>AEs leading to discontinuation from the study</td>
<td>26 (6.5%)</td>
<td>17 (4.3%)</td>
</tr>
<tr>
<td>Most Frequent AEs</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>1: COVID-19</td>
<td>32 (8.0%)</td>
<td>36 (9.0%)</td>
</tr>
<tr>
<td>2: Urinary Tract Infection</td>
<td>31 (7.8%)</td>
<td>29 (7.3%)</td>
</tr>
<tr>
<td>3: Fall</td>
<td>30 (7.5%)</td>
<td>30 (7.5%)</td>
</tr>
<tr>
<td>4: Dizziness</td>
<td>21 (5.3%)</td>
<td>1 (0.3%)</td>
</tr>
<tr>
<td>5: Headache</td>
<td>18 (4.5%)</td>
<td>11 (2.8%)</td>
</tr>
<tr>
<td colspan="3">&#x2A;Based on the intent-to-treat population &#x2A;&#x2A;Based on the safety population BID = twice daily AD = Alzheimer's disease MMSE = Mini-Mental State Examination</td>
</tr>
</tbody>
</table>
</figure>
 Cassava will continue to review all of the data and evaluate next steps. We plan to share the detailed results at a future medical meeting.
Eric Schoen, Chief Financial Officer at Cassava commented, "We remain focused on the interests of Cassava shareholders and are committed to enhancing shareholder value. Cassava is well-capitalized with approximately $149.0 million in cash and cash equivalents as of the end of the third quarter of 2024."

SAVA

Cassava Sciences Halts Alzheimer's Drug Trials After Phase 3 Results

Are you tired of the endless political drama? Maybe you're feeling like it's time for a real change, far from all the noise. How about this – a move to an idyllic Italian village where homes cost as little as one dollar? It sounds almost too good to be true, but Ollolai, a charming spot in Sardinia, Italy, is doing just that. They're welcoming frustrated Americans with open arms, offering a chance to swap out the tension of modern politics for the simple pleasures of small-town Italian life.
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
This picturesque village has seen its population shrink drastically over the past decades. To breathe new life into the community, the local authorities devised a bold idea: sell abandoned, rundown homes for a mere €1 or $1. However, these homes need some love and renovation. For anyone willing to work, this is <a href="https://www.benzinga.com/markets/24/10/41149295/real-estate-in-italy-is-a-goldmine-for-investors-california-resident-snags-6-bedroom-2-kitchen-home">an amazing opportunity</a> to build a dream European escape from the ground up.
With its cobbled streets, historic stone houses and an air of tranquillity, Ollolai is a <a href="https://www.benzinga.com/news/24/01/36759767/you-might-be-eligible-to-buy-a-house-in-croatia-for-13-cents">hidden gem</a> just waiting for people to discover its charm and immerse in a different way of life – one where neighbors know each other, the air is clean and the food comes straight from local farms. It's a chance to live slowly and meaningfully, to enjoy simple pleasures like a morning espresso on a sunny terrace or an evening stroll with views of the rolling hills.
Trending: Invest in $20+ trillion home equity market today across cities like Austin, Miami, and Los Angeles through a <a href="https://www.benzinga.com/money/nada-cityfunds">unique 5-year term fund targeting a 14-20% IRR with minimums as low as $2,500</a>
<h2 class="wp-block-heading">Why Now?</h2>
Although the village has been selling <a href="https://www.benzinga.com/real-estate/24/05/39028524/a-look-at-japans-reverse-housing-crisis-where-millions-of-homes-sit-vacant">abandoned houses</a> for years, the push to attract American buyers has intensified in the wake of recent election results in the United States. Feeling disillusioned by the political situation? Ollolai's mayor, Francesco Columbu, told CNN that Americans are the perfect fit for the village's revival. To sweeten the deal, the village offers a fast-track process specifically for U.S. buyers, making securing your slice of Italian paradise easier than ever.
Not only are €1 houses available, but there are also move-in-ready homes for those who prefer a simpler transition. Prices for these homes are more substantial, reaching up to €100,000, but they come with the benefit of being ready for immediate living – no renovation required.
See Also: Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a>
<h2 class="wp-block-heading">What to Expect in Ollolai</h2>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Ollolai, Italy: Hundreds of abandoned homes selling for just one euro. The stone-built dwellings need major renovations. Reporter <a href="https://twitter.com/hughwhitfeld?ref_src=twsrc%5Etfw">@HughWhitfeld</a>​. Cameraman @7_Cannon. <a href="https://twitter.com/hashtag/Ollolai?src=hash&amp;ref_src=twsrc%5Etfw">#Ollolai</a> <a href="https://twitter.com/hashtag/7News?src=hash&amp;ref_src=twsrc%5Etfw">#7News</a> <a href="https://t.co/eHGdGwYGHl">pic.twitter.com/eHGdGwYGHl</a>
&mdash; 7NEWS Sydney (@7NewsSydney) <a href="https://twitter.com/7NewsSydney/status/973892751317233665?ref_src=twsrc%5Etfw">March 14, 2018</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Life in Ollolai is peaceful and connected to nature. The village is located in a largely untouched region, offering clear air, scenic landscapes and a chance to unplug. Per CNN, many of the houses available for sale are old farmers' and shepherds' dwellings made of local granite, giving them a rustic charm that's hard to find anywhere else. Some are even fully furnished, with modern amenities while retaining their traditional style.
Read Next:
<ul>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>

Real Estate

'Start Building Your European Escape' – Italian Village Offers $1 Homes For Americans Frustrated By Election Results

RKLB: 17% &#x7C; <a href="https://www.benzinga.com//node/42160144">Rocket Lab Secures $23.9M Grant to Boost Semiconductor Production in New Mexico</a>
&nbsp;
BBWI: 15% &#x7C; <a href="https://www.benzinga.com//node/42159985">Bath &amp; Body Works Q3 2024 Adj. EPS $0.49 Beats $0.47 Estimate, Sales $1.610B Beat $1.579B Estimate</a>
&nbsp;
MARA: 6% &#x7C; <a href="https://www.benzinga.com//node/42159675">Barclays Initiates Coverage On MARA Holdings with Equal-Weight Rating, Announces Price Target of $27</a>

Trading Ideas

MARA

Market-Moving News for November 25th

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $69 price target.

Reiteration

RYTM

HC Wainwright & Co. Reiterates Buy on Rhythm Pharmaceuticals, Maintains $69 Price Target

MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) has been described as the &#8220;Bitcoin magnet,&#8221; attracting billions of dollars in global capital <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42138209/microstrategy-trading-at-insane-256-premium-to-bitcoin-holdings-research-shows">through its unprecedented Bitcoin</a> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) treasury strategy. 
What Happened: Bernstein's report on Monday highlights MicroStrategy's role in mainstreaming Bitcoin on Wall Street, projecting the company could hold 4% of the global Bitcoin supply by 2033, up from 1.7% today.
However, skeptics, including popular analyst &#8216;Kryptokrates,&#8217; caution that the strategy comes with significant risks, raising questions about its long-term viability.
Bernstein lauded MicroStrategy's innovative model, which <a href="https://www.benzinga.com/24/11/42151809/michael-saylor-reveals-microstrategy-is-making-500m-a-day-with-bitcoin-may-very-well-be-the-most-profitable-company-in-the-us-growing-the-fastest-right-now">leverages convertible debt</a> and equity raises to amass Bitcoin.
The firm's current holdings of ~300,000 BTC are valued at $32 billion, acquired at an average cost of ~$49,900 per Bitcoin. 
Bernstein projects MicroStrategy could increase its holdings to 4% of the world's Bitcoin by 2033, assuming Bitcoin reaches $1 million per coin.
"MicroStrategy's Bitcoin treasury model is unprecedented," Bernstein noted. "A company on an insatiable path to attract billions in global capital to invest in Bitcoin."
MicroStrategy has raised more than $7 billion in convertible debt, with a long-term plan to secure $42 billion in capital by 2027. 
<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42138209/microstrategy-trading-at-insane-256-premium-to-bitcoin-holdings-research-shows">Its approach</a> involves adding Bitcoin to the balance sheet, increasing stock volatility and using convertible debt to enable low-cost capital raises.
Bernstein sees this strategy as <a href="https://www.benzinga.com/24/11/42151809/michael-saylor-reveals-microstrategy-is-making-500m-a-day-with-bitcoin-may-very-well-be-the-most-profitable-company-in-the-us-growing-the-fastest-right-now">sustainable</a> under favorable market conditions, raising its price target for the stock to $600, a 42% upside from its current $421.88.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42145634/cboe-to-launch-cash-settled-bitcoin-index-options">Cboe To Launch Cash-Settled Bitcoin Index Options</a>
Institutional Appeal vs. Retail Risks
While Bernstein remains bullish, critics like Kryptokrates argue that MicroStrategy's financial engineering introduces systemic risks.
"Saylor created the perfect financial perpetual motion machine. It works until it doesn't. The question isn't if, but when,&#8221; the analyst <a href="https://x.com/Kryptokrates/status/1860381306103746766">tweeted</a>.
Kryptokrates outlined several potential vulnerabilities:
<ol>
<li>Market Risk: "A Bitcoin price collapse could trigger a systemic failure."</li>
<li>Leverage Concerns: "MicroStrategy's total debt is ~$3 billion—a massive bet on ‘number go up.'"</li>
<li>Regulatory Pressure: "Any regulatory crackdown could disrupt the model."</li>
<li>Retail Investor Risk: "Small investors think they're ‘buying Bitcoin exposure' but are actually buying systemic risk."</li>
</ol>
Kryptokrates also flagged warning signs such as increasing convertible note issuances and more aggressive Bitcoin buying, suggesting heightened financial risk as the company scales.
Bernstein emphasized the appeal of <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42121936/bitcoin-boom-20-microstrategy-gains-traction-as-a-leveraged-bet-on-crypto-growth">MicroStrategy's strategy</a> for institutional investors, citing high liquidity, Bitcoin exposure, and regulatory compliance.
Kryptokrates, however, noted that retail investors might misunderstand the risks, tweeting, "Nothing is free in finance. Leverage works both ways. Always check the fine print."
The best-case scenario, according to Bernstein, sees MicroStrategy continuing to capitalize on Bitcoin's price appreciation, reaching $1 million per coin by 2033. 
However, Kryptokrates offered a stark contrast: "Worst case—Bitcoin crashes, notes demand repayment, share price collapses, system fails."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42143918/strike-ceo-jack-mallers-bitcoin-is-the-best-performing-asset-in-the-history-of-mankind">Strike CEO Jack Mallers: &#8216;Bitcoin Is The Best Performing Asset In The History Of Mankind&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

MicroStrategy Is The 'Bitcoin Magnet,' Says Bernstein, But Not Everybody's Sold: 'Nothing Is Free In Finance,' Says One Analyst

Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending

FLEX, PNST and CAN among pre-market losers

NEXI, MTC and MOLN among pre-market losers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Thursday morning as we check out all of the latest news moving shares today!



Moving stocks this morning are earnings reports, disclosed stakes in companies and more.



Let&rsquo;s get into that news down below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>JX Luxventure (NASDAQ:<a href="https://investorplace.com/stock-quotes/jxjt-stock-quote/">JXJT</a>) stock is rocketing more than 345% alongside heavy trading.</li>



<li>China Natural Resources (NASDAQ:<a href="https://investorplace.com/stock-quotes/chnr-stock-quote/">CHNR</a>) shares are soaring over 277% with strong early morning trading.</li>



<li>SoundHound AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/soun-stock-quote/">SOUN</a>) stock is surging more than 67% after Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>) <a href="https://finance.yahoo.com/news/nvidia-reports-stakes-arm-soundhound-222448317.html">reported a stake in the company</a>.</li>



<li>Meihua International Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/mhua-stock-quote/">MHUA</a>) shares are gaining over 51% with strong pre-market trading today.</li>



<li>Nouveau Monde Graphite (NYSE:<a href="https://investorplace.com/stock-quotes/nmg-stock-quote/">NMG</a>) stock is increasing more than 45% after <a href="https://www.businesswire.com/news/home/20240214552719/en/NMG-Announces-Offtake-Agreement-with-GM-for-Canadian-Graphite-and-US150-Million-Equity-Investment">signing a supply agreement</a> with General Motors (NYSE:<a href="https://investorplace.com/stock-quotes/gm-stock-quote/">GM</a>).</li>



<li>Nano X Imaging (NASDAQ:<a href="https://investorplace.com/stock-quotes/nnox-stock-quote/">NNOX</a>) shares are rising over 38% as Nvidia also revealed a stake in this company.</li>



<li>OLB Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/olb-stock-quote/">OLB</a>) stock is climbing more than 38% on Thursday morning.</li>



<li>Roma Green Finance (NASDAQ:<a href="https://investorplace.com/stock-quotes/roma-stock-quote/">ROMA</a>) shares are jumping over 26% with heavy pre-market trading.</li>



<li>Scorpius (NYSEMKT:<a href="https://investorplace.com/stock-quotes/scpx-stock-quote/">SCPX</a>) stock is getting a 25% boost this morning.</li>



<li>Greenpro Capital (NASDAQ:<a href="https://investorplace.com/stock-quotes/grnq-stock-quote/">GRNQ</a>) shares are up more than 24% as it sees strong trading early this morning.</li>
</ol><h2>Top 10 Losers</h2>



<ol><li>Treasure Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/tgl-stock-quote/">TGL</a>) stock is plummeting close to 44% after releasing a <a href="https://www.nasdaq.com/press-release/treasure-global-reports-second-quarter-fiscal-year-2024-results-2024-02-14">mixed fiscal Q2 2024 earnings report</a>.</li>



<li>Cineverse (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnvs-stock-quote/">CNVS</a>) shares are retreating over 37% following the <a href="https://www.nasdaq.com/press-release/cineverse-reports-third-quarter-fiscal-year-2024-results-2024-02-14">release of its Q3 earnings report</a>.</li>



<li>Renalytix (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnlx-stock-quote/">RNLX</a>) stock is tumbling more than 31% after <a href="https://www.nasdaq.com/press-release/renalytix-reports-financial-results-for-second-quarter-of-fiscal-year-2024-2024-02-15">releasing results for its latest quarter</a>.</li>



<li>Fresh2 Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/fres-stock-quote/">FRES</a>) shares are taking an over 30% beating on Thursday morning.</li>



<li>Clean Energy Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/cety-stock-quote/">CETY</a>) stock is sliding more than 28% without any obvious news today.</li>



<li>Earlyworks (NASDAQ:<a href="https://investorplace.com/stock-quotes/elws-stock-quote/">ELWS</a>) stock is pulling back over 29% <a href="https://investorplace.com/2024/02/why-is-earlyworks-elws-stock-up-340-today/">after a massive rally yesterday</a>.</li>



<li>Upexi (NASDAQ:<a href="https://investorplace.com/stock-quotes/upxi-stock-quote/">UPXI</a>) shares are falling more than 26% <a href="https://finance.yahoo.com/news/upexi-reports-fiscal-second-quarter-210500871.html">following a rough Q2 earnings report</a>.</li>



<li>Addentax (NASDAQ:<a href="https://investorplace.com/stock-quotes/atxg-stock-quote/">ATXG</a>) stock is dropping over 26% with its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318065266&amp;type=PDF&amp;symbol=ATXG&amp;cdn=1f758177ea2228606438e3a5fa8aaf7f&amp;companyName=Addentax+Group+Corp.&amp;formType=10-Q&amp;formDescription=General+form+for+quarterly+reports+under+Section+13+or+15%28d%29&amp;dateFiled=2024-02-14">latest earnings release</a>.</li>



<li>Healthcare Triangle (NASDAQ:<a href="https://investorplace.com/stock-quotes/hcti-stock-quote/">HCTI</a>) shares are slipping more than 25% <a href="https://seekingalpha.com/news/4067041-healthcare-triangle-stock-jumps-on-new-saas-solution-to-drive-ai-integration-in-healthcare?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain">following a rally late yesterday</a>.</li>



<li>United States Antimony&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/uamy-stock-quote/">UAMY</a>) stock closes out our pre-market stock movers down over 24%.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/02/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-feb-15th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

ATXG, CETY and TELO among pre-market losers

These Industrials stocks are trading higher:-Intuitive Machines Inc (LUNR) stock is trading at $6.80, a rise of $1.82, or 37.15%, on high volume.  Intuitive Machines Inc gets a Sentiment Score of Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $5.63.  -Guar

Industrials Stocks Making Moves Thursday: LUNR, GFAI, LICN, MPU, ATXG, MTW, UGRO, UPWK

Addentax signs MOU to develop AI logistics system

Addentax signs MOU to develop AI logistic system

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Addentax Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/atxg-stock-quote/">ATXG</a>) just reported results for the fourth quarter of 2023.<ul><li>Addentax Group reported earnings per share of 29 cents.</li><li>The company reported revenue of $1.30 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/07/atxg-stock-earnings-addentax-group-for-q4-of-2023/">ATXG Stock Earnings: Addentax Group Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ATXG Stock Earnings: Addentax Group Reported Results for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Addentax Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/atxg-stock-quote/">ATXG</a>) just reported results for the first quarter of 2024.<ul><li>Addentax Group reported earnings per share of -25 cents.</li><li>The company reported revenue of $851,033.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/atxg-stock-earnings-addentax-group-for-q1-of-2024/">ATXG Stock Earnings: Addentax Group Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ATXG Stock Earnings: Addentax Group Reported Results for Q1 2024

Addentax Group Corp. has announced the signing of a Memorandum of Understanding, or MOU, for nationwide strategic cooperation with Shenzhen Yingbin...

ATX Group, Inc. signs MOU for strategic cooperation with Shenzhen Yingbin Brand

ABAT

ABVC

AISP

ATXG

AUPH

BBLG

BETS

BNZI

BREA

BTBT

BTDR

CETY

CHNR

CLSK

CNVS

DBGI

ELWS

ESPR

FLEX

FRES

FSLY

FWBI

GFAI

GREE

GRNQ

HALL

HCTI

HIVE

ICCT

IINN

JXJT

LEXX

LICN

LUNR

MANU

MBLY

MHUA

MOLN

NEXI

NNOX

OTLY

PNST

RIOT

RNLX

ROMA

SABR

SCPX

SCYX

SIDU

SOUN

TELO

TWLO

UAMY

UGRO

UPWK

UPXI

WULF

YETI

ZCAR

Press Releases

Addentax Group Corp. Announces Signing of MOU for Strategic Cooperation with Zhongjiu Yihe

Addentax Group Corp. is Launching "Tourism-As-A-Service" Platform with Artificial Intelligence and Block-Chain Tools to Incubate Local and Overseas Pan-Entertainment and Tourism Services

Addentax Group Corp. and Regina Miracle International (Holdings) Limited Entered into a Collaboration Agreement to Enhance Textile and Garment Industry Services

Addentax Group Corp. and Dezhong Xinghui Collaborate to Develop AI Logistic System, Facilitating Breakthroughs in Logistics Delivery

Addentax Group Corp. Announces Private Placements of its Common Stock

Addentax Group Corp. Announces Signing of MOU for Strategic Cooperation with Shenzhen Yingbin Brand Development Co., Ltd.

Air T

Air Transport Services Group, Inc - Common Stock

Air Transport Services Gr

BEST Inc. American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

BEST

C.H. Robinson Worldwide, Inc. - Common Stock

C.H. Robinson Worldwide

Freightos

Expeditors International of Washington, Inc. Common Stock

Expeditors Intl

FedEx

BingEx Limited - American Depositary Shares

BingEx

Freight Technologies, Inc. - Ordinary Shares

Freight Technologies

Forward Air

Globavend Holdings

GXO Logistics

Hub Group

Jayud Global Logistics Limited - Class A Ordinary Shares

Jayud Global Logistics

PS International Group Ltd. - Ordinary Shares

PS International Group

Radiant Logistics

Shengfeng Development Limited - Class A Ordinary Shares

Shengfeng Development

United Parcel Service

ZTO Express (Cayman) Inc. American Depositary Shares, each representing one Class A ordinary share.

ZTO Express (Cayman)

Comments

Addentax Group

Addentax Group (ATXG) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO